SVB Wealth LLC Cuts Stake in Medtronic PLC $MDT

SVB Wealth LLC lessened its position in Medtronic PLC (NYSE:MDT) by 17.7% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 27,552 shares of the medical technology company’s stock after selling 5,942 shares during the period. SVB Wealth LLC’s holdings in Medtronic were worth $2,155,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in MDT. Madison Asset Management LLC increased its holdings in Medtronic by 15.0% in the fourth quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock valued at $18,752,000 after buying an additional 25,527 shares in the last quarter. Gradient Investments LLC grew its holdings in shares of Medtronic by 3.9% in the 2nd quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company’s stock worth $38,842,000 after acquiring an additional 18,509 shares during the period. Czech National Bank increased its stake in Medtronic by 4.7% in the 2nd quarter. Czech National Bank now owns 365,443 shares of the medical technology company’s stock valued at $28,589,000 after purchasing an additional 16,292 shares in the last quarter. Cerity Partners LLC raised its holdings in Medtronic by 12.7% during the fourth quarter. Cerity Partners LLC now owns 791,015 shares of the medical technology company’s stock worth $75,988,000 after purchasing an additional 89,111 shares during the last quarter. Finally, National Pension Service raised its holdings in Medtronic by 1.0% during the fourth quarter. National Pension Service now owns 2,982,411 shares of the medical technology company’s stock worth $286,490,000 after purchasing an additional 28,269 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have commented on MDT shares. BTIG Research boosted their target price on Medtronic from $91.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, September 1st. JPMorgan Chase & Co. cut their price target on Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $92.00 price objective on shares of Medtronic in a research report on Thursday, September 3rd. Mizuho set a $115.00 price objective on shares of Medtronic in a research note on Wednesday, September 2nd. Finally, Leerink Partners dropped their target price on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a report on Thursday, June 4th. Nineteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus price target of $103.92.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic raised its fiscal 2027 organic revenue-growth outlook and increased the lower end of its adjusted earnings forecast after quarterly results exceeded expectations. Cardiovascular devices were the primary growth engine, while surgical products also contributed to broad-based expansion. Medtronic Raised its Outlook as Heart Devices Accelerate, But Can the Momentum Last?
• Positive Sentiment: Recent results showed 13.7% year-over-year revenue growth, $9.76 billion in quarterly revenue versus a $9.55 billion consensus estimate, and adjusted EPS of $1.45 versus expectations of $1.39. The performance suggests improving demand across Medtronic’s cardiovascular and surgical franchises. Medtronic Q1 2027 Earnings Call Transcript
• Positive Sentiment: Medtronic remains attractive to income-focused investors, offering a roughly 3% dividend yield and having increased its dividend for 49 consecutive years. The company is potentially two years away from reaching “Dividend King” status, which could support long-term shareholder interest. Medtronic Is on the Cusp of Becoming a Dividend King
• Neutral Sentiment: Analysts view the improved growth and earnings outlook favorably, but investors remain selective because Medtronic must demonstrate that its cardiovascular acceleration is sustainable beyond the latest quarter.
• Negative Sentiment: Margin pressure, foreign-exchange effects, execution risks and intense medical-device competition could limit the benefit of stronger sales growth. These concerns help explain why the stock has not fully reflected the improved outlook. Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum

Medtronic Price Performance

Medtronic stock opened at $92.01 on Thursday. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The stock has a market capitalization of $117.69 billion, a P/E ratio of 22.66, a P/E/G ratio of 2.17 and a beta of 0.56. The firm’s 50-day moving average is $87.58 and its two-hundred day moving average is $85.17. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company’s revenue was up 13.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities analysts predict that Medtronic PLC will post 5.96 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio is currently 70.94%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.